Most reported GI events were mild to moderate in severity and predominantly occurred during the dose-escalation phase across all treatment groups (11)
The FDA has been clear: outside of patient-specific medical exceptions, mass compounding of these medications is no longer permitted under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [8]
Ultimately, they discovered the drug was able to reduce the risk for cardiovascular events by about 20% specifically in adults who are 45 and older, considered overweight or obese, not diabetic, and who have previously had a cardiovascular event
The psychological impact of these changes shouldnt be underestimated
Depending on how well you tolerate the medication, any side effects you experience, and your blood sugar control, your healthcare provider may increase the dosage of Rybelsus to the maximum dose of 14 mg once daily